Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A
NASDAQ: BRKRP0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Frank H. Laukien
- Employees
- 11,396
- Headquarters
- Billerica, United States
- IPO year
- 2025
- Market cap
- $8.7B
- Website
- https://www.bruker.com
Loading BRKRP…
Loading profile data…Frequently asked questions about BRKRP
What does Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A (BRKRP) do?
Bruker Corporation specializes in the creation, production, and global distribution of advanced scientific instrumentation and comprehensive analytical and diagnostic systems. These sophisticated tools empower researchers and industries to delve into the intricate details of life and various materials, from microscopic to molecular and cellular...
Where does BRKRP trade?
Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A (BRKRP) trades on the NASDAQ Global Select.
What sector is BRKRP in?
Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A (BRKRP) operates in the Healthcare sector, specifically in the Medical - Devices industry.
Who is the CEO of Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A?
Frank H. Laukien is the chief executive officer of Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A (BRKRP).
Where is Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A headquartered?
Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A is headquartered in United States.
Does BRKRP pay a dividend?
Yes — Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A (BRKRP) paid a trailing twelve-month dividend of USD 11.65 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did BRKRP go public?
Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A (BRKRP) completed its initial public offering in 2025.